


**Product Name** : VTP50469  
**Cat. No.** : PC-72792  
**CAS No.** : 2169916-18-9  
**Molecular Formula** : C<sub>32</sub>H<sub>47</sub>FN<sub>6</sub>O<sub>4</sub>S  
**Molecular Weight** : 630.3364  
**Target** : Histone Methyltransferase (HMTase)  
**Solubility** :



## Biological Activity

VTP50469 (VTP 50469, SNDX-50469) is potent, selective, orally active inhibitor of Menin-MLL interaction with  $K_i$  of 104 pM. VTP50469 treatment led to a profound reduction in cell proliferation in a concentration-dependent manner in MLL-r cell lines carrying but not in those with WT MLL (HL-60, REH, K562, murine MOZ-TIF2).

VTP50469 treatment rapidly suppresses MLL-fusion target gene expression, induces global changes in Menin and selective changes in MLL chromatin occupancy.

VTP50469 treatment can eradicate disease in PDX models of MLL-r acute leukemia.

## References

Krivtsov AV, et al. Cancer Cell. 2019 Dec 9;36(6):660-673.e11.

Heikamp EB, et al. Blood. 2021 Sep 28;blood.2021012806.

Warren Fiskus, et al. Blood Cancer J. 2022 Jan 11;12(1):5.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com